SBI Fund Management Unlisted Shares
SBI Mutual Fund buys Alkem Laboratories shares for Rs 300 crore
msn.com
2 min read
SBI Mutual Fund Raises Alkem Stake with ₹300 Cr Buy.
Expert Analysis :
SBI MF Investment: SBI Mutual Fund bought additional Alkem Laboratories shares for ₹300 crore via an open market transaction on 21 Feb 2025.
Block Deal Details: SBI Mutual Fund acquired 6.41 lakh shares (0.54% stake) in Alkem Laboratories, as per NSE block deal data.
Stake & Price Details: SBI Mutual Fund bought shares at an average price of ₹4,680, raising its stake in Alkem from 2.16% to 2.7%, with a total transaction value of ₹300.32 crore.
Promoter Offloading: Samprada and Nanhamati Singh Family Trust (Alkem promoters) sold the same 6.41 lakh shares, as per NSE data.
Stock Decline: Alkem Laboratories’ stock fell 2.54%, closing at ₹4,600.05 on the NSE on Friday.
SBI Mutual Fund raised its stake to 2.7% via a ₹300.32 crore buy, despite a 2.54% stock dip.
Precize Daily Pulse
The latest news in the world of Unlisted Shares, summarised by our experts.
Company
Our Office
Office No. 1219, The Summit Business Park, Andheri Kurla Road, Andheri East, Mumbai, Maharashtra - 400093
Find us on Googlesupport@precize.in
+91 7738336457
All trademarks and logos or registered trademarks and logos found on this Site or mentioned herein belong to their respective owners and are solely used for informational and educational purposes.
The material presented in this advertisement is for informational purposes only and should not be construed as investment advice or investment availability. It is not a recommendation of, or an offer to sell or solicitation of an offer to buy, any particular unlisted share, security, strategy, or investment product. Investing in the private market and securities involves risks, including the potential loss of money, and past performance does not guarantee future results. Market trends, data interpretations, graph projections are provided for informational and illustrative purposes and may not reflect actual future performance. Nothing on this website should be construed as personalized investment advice or should not be treated as legal, financial, or any other form of advice. Precize is not liable for financial or any other form of loss incurred by the user or any affiliated party based on information provided herein.
Precize is neither a stock exchange nor does it intend to get recognized as a stock exchange under the Securities Contracts Regulation Act, 1956. Precize is not authorized by the capital markets regulator to solicit investments. The securities traded on these platforms are not traded on any regulated exchange.
The website will be updated regularly.
Copyright © 2026 - Precize - All Rights Reserved